BACKGROUND: In the absence of medical contraindications, survival after undergoing breast-conserving therapy (BCT), mastectomy (M), and mastectomy with immediate reconstruction (MIR) is equal. The authors studied demographic factors to identify the variables that differed significantly among women making different surgical choices. METHODS: Women with ductal carcinoma in situ or clinical Stage I or II breast carcinoma with no contraindications for BCT or MIR who were treated between 1995 and 1998 were identified from a prospectively collected data base. Demographic and tumor factors were compared using the Fisher exact test. RESULTS: There were 578 women with 586 tumors who did not have contraindications for BCT or MIR. Among this group, 85.2% of women chose BCT, 9.2% of women chose M, and 5.6% of women chose MIR. Women undergoing M alone were older and were more likely to have Stage II carcinoma compared with women undergoing BCT. Patients undergoing M or MIR were more likely to have had a prior breast biopsy compared with patients who chose BCT. Marital status and employment approached significance (P = 0.06); however, a family history of breast carcinoma was not a predictor of treatment choice. CONCLUSIONS: The current findings suggest a need for patient education strategies that emphasize the lack of influence of age and prior breast biopsy on the use of BCT. Differences in demographic variables may reflect true variations in patient preference among groups, emphasizing the need to address the spectrum of treatment options with patients. Copyright 2002 American Cancer Society.
BACKGROUND: In the absence of medical contraindications, survival after undergoing breast-conserving therapy (BCT), mastectomy (M), and mastectomy with immediate reconstruction (MIR) is equal. The authors studied demographic factors to identify the variables that differed significantly among women making different surgical choices. METHODS:Women with ductal carcinoma in situ or clinical Stage I or II breast carcinoma with no contraindications for BCT or MIR who were treated between 1995 and 1998 were identified from a prospectively collected data base. Demographic and tumor factors were compared using the Fisher exact test. RESULTS: There were 578 women with 586 tumors who did not have contraindications for BCT or MIR. Among this group, 85.2% of women chose BCT, 9.2% of women chose M, and 5.6% of women chose MIR. Women undergoing M alone were older and were more likely to have Stage II carcinoma compared with women undergoing BCT. Patients undergoing M or MIR were more likely to have had a prior breast biopsy compared with patients who chose BCT. Marital status and employment approached significance (P = 0.06); however, a family history of breast carcinoma was not a predictor of treatment choice. CONCLUSIONS: The current findings suggest a need for patient education strategies that emphasize the lack of influence of age and prior breast biopsy on the use of BCT. Differences in demographic variables may reflect true variations in patient preference among groups, emphasizing the need to address the spectrum of treatment options with patients. Copyright 2002 American Cancer Society.
Authors: Warren H Tseng; Thomas R Stevenson; Robert J Canter; Steven L Chen; Vijay P Khatri; Richard J Bold; Steve R Martinez Journal: Plast Reconstr Surg Date: 2010-12 Impact factor: 4.730
Authors: Sarah T Hawley; Nancy K Janz; Ann Hamilton; Jennifer J Griggs; Amy K Alderman; Mahasin Mujahid; Steven J Katz Journal: Patient Educ Couns Date: 2008-11
Authors: Jing Zhou; Lindsey Enewold; Shelia H Zahm; Ismail Jatoi; Craig Shriver; William F Anderson; Diana D Jeffery; Abegail Andaya; John F Potter; Katherine A McGlynn; Kangmin Zhu Journal: Am J Surg Date: 2013-07-16 Impact factor: 2.565
Authors: Rachel C Shelton; Grace Clarke Hillyer; Dawn L Hershman; Nicole Leoce; Dana H Bovbjerg; Jeanne S Mandelblatt; Lawrence H Kushi; Lois Lamerato; S David Nathanson; Christine B Ambrosone; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2012-12-22 Impact factor: 4.872
Authors: Claire Kim; Laurel Liang; Frances C Wright; Nicole J Look Hong; Gary Groot; Lucy Helyer; Pamela Meiers; May Lynn Quan; Robin Urquhart; Rebecca Warburton; Anna R Gagliardi Journal: Breast Cancer Res Treat Date: 2017-12-23 Impact factor: 4.872